Society Logo
ME/CFS Australia Ltd
Please Click Here To Donate ME/CFS Australia (SA) Inc
 
Facebook
 
ME/CFS AUSTRALIA (SA) INC

Registered Charity 698

Email:
sacfs@sacfs.asn.au

Mailing address:
PO Box 28,
Hindmarsh,
South Australia 5007

Office:
Suite 506,
North Terrace House,
19 North Terrace,
Hackney, SA, 5069


Phone:
1300 128 339

Office Hours:
Wednesdays, 11am-3pm

ME/CFS Australia (SA) Inc supports the needs of sufferers of Myalgic Encephalomyelitis, Chronic Fatigue Syndrome and related illnesses. We do this by providing services and information to members.

Disclaimer

ME/CFS Australia (SA) Inc aims to keep members informed of various research projects, diets, medications, therapies, news items, etc. All communication, both verbal and written, is merely to disseminate information and not to make recommendations or directives.

Unless otherwise stated, the views expressed on this Web site are not necessarily the official views of the Society or its Committee and are not simply an endorsement of products or services.

Become a Member
PDF Application Form (PDF, 277KB)
Why become a member?

Unsuspected primary hyperparathyroidism common in Fibromyalgia patients

Saturday 30 November 2013

 

From Ob.Gyn. News:

 

Hyperparathyroidism
 

Unsuspected primary hyperparathyroidism common in fibromyalgia patients

By: BRUCE JANCIN, Ob.Gyn. News Digital Network

SAN DIEGO – The prevalence of unsuspected primary hyperparathyroidism among patients diagnosed with fibromyalgia was 11% in a small exploratory study, Dr. Michael Tsoukas reported at the annual meeting of the American College of Rheumatology.

That’s roughly 100-fold greater than the prevalence of primary hyperparathyroidism in the general population, noted Dr. Tsoukas of McGill University, Montreal.

The classic symptoms of primary hyperparathyroidism include musculoskeletal pain, fatigue, mood disorders, and sleep disturbances, a clinical picture closely mimicking that of fibromyalgia, he observed.

Dr. Tsoukas presented a retrospective study of a convenience sample of 38 consecutive patients with a primary diagnosis of fibromyalgia attending a multidisciplinary tertiary care pain center where physicians obtained routine blood tests. Four of the 38, or 11%, met criteria for the biochemical diagnosis of hyperthyroidism. Two had what’s known as normohormonal hyperparathyroidism, marked by a serum ionized calcium elevated above 1.32 mmol/L or 5.3 mg/dL, with inappropriately high parathyroid hormone levels. The other two had a parathyroid hormone level in excess of 9.3 pmol/L or 93 pg/mL, with inappropriately nonsuppressed calcium.

This was a pilot study. Four cases of unsuspected hyperparathyroidism hardly make for a definitive study. But this was the first study to look at hyperparathyroidism in fibromyalgia patients, and given how common fibromyalgia is and the difficulties and frustrations often encountered in its treatment, these intriguing preliminary findings warrant large, prospective, multicenter studies to further clarify the relationship between these two disorders with closely similar symptoms, Dr. Tsoukas concluded.

He reported having no financial conflicts of interest in this unfunded study.

bjancin@frontlinemedcom.com

The above originally appeared here.

 


Arrow right

More Fibromyalgia News

 


 

blog comments powered by Disqus
Previous Previous Page